Omalizumab: an underutilized treatment option in bullous pemphigoid patients with co-morbidities

D. De*, A. Kaushik, S. Handa, R. Mahajan, E. Schmidt

*Corresponding author for this work
20 Citations (Scopus)
Original languageEnglish
JournalJournal of the European Academy of Dermatology and Venereology
Volume35
Issue number7
Pages (from-to)e469-e472
Number of pages4
ISSN0926-9959
DOIs
Publication statusPublished - 07.2021

Funding

The study was supported in part by structural funds of the Clinical Research Unit Pemphigoid Diseases (KFO 303) and the Cluster of Excellence Precision Medicine in Chronic Inflammation (EXC 2167) both funded by Deutsche Forschungsgemeinschaft. We are grateful to Ms Shilpa for immunological investigations and Vanessa Krull, L?beck, for excellent technical assistance with the IgE-specific BP180 and BP230 ELISA. The study was supported in part by structural funds of the Clinical Research Unit (KFO 303) and the Cluster of Excellence Precision Medicine in Chronic Inflammation (EXC 2167) both funded by Deutsche Forschungsgemeinschaft. We are grateful to Ms Shilpa for immunological investigations and Vanessa Krull, Lübeck, for excellent technical assistance with the IgE‐specific BP180 and BP230 ELISA. Pemphigoid Diseases

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)

Cite this